Biotech vets launch a neuro startup with $54.5M to kickstart R&D
More than 2 years after Kathleen Sereda Glaub and Anthony Ford helped line up a $1.25 billion deal to sell Afferent Pharmaceuticals to Merck, the two are back with a new startup that has rounded up $54.5 million in venture cash with plans to pursue some new approaches to neurosciences.
Licensing tech out of the lab of Stanford’s Mehrdad Shamloo, the two execs have kickstarted CuraSen Therapeutics into existence, working on small molecules that are designed to target receptors “to compensate for critical neuronal and glial functions that have otherwise been lost due to degeneration.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.